CureVac has signed a new licensing agreement with GSK shortly after announcing the decision to reduce its workforce by 30% and refocus its research and development priorities.
As investors and big pharma pile on developers of antibody-drug conjugates (ADCs), Bright Peak Therapeutics has attracted $90 million based on the promise of a related type of technology called immunoconjugates.
Alchemab Therapeutics, an antibody discovery firm known for identifying natural antibodies in disease-resistant individuals, has published a peer-reviewed article titled "Predictability of B cell clonal persistence and immunosurveillance in breast...
Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.
Angle, a liquid biopsy company with circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, has launched its Portrait PD-L1 test for the evaluation of PD-L1 protein expression on CTCs.
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
Bolt Biotherapeutics, a San Francisco based company developing a platform for cancer immunotherapy, will present its phase 1/2 dose escalation study of BDC-1001 at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, being held in...
Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases with high unmet medical needs, has announced an update to its oral vaccine programme.
A-Alpha Bio, a synthetic biology and machine learning company, has announced its collaboration with Gilead that aims to advance the design of human immunodeficiency virus (HIV) therapies.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.
AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.
A newly approved patent will allow CEL-SCI to explore using cellular delivery to prevent and treat infectious diseases using its LEAPS technology, the firm says.
Merck Sharp & Dohme (MSD) plans to build a biologics facility at a former small molecule manufacturing site in Swords, Ireland, which it closed last year.
GigaGen has relocated laboratory and office space in San Francisco to boost development of antibody therapeutics for patients with immune dysregulation.
TxCell SA has developed the production process for it range of CAR-Treg based therapies and is preparing to transfer it to its CMO ahead of first-in-human trials.
Yposkesi will make lentiviral vectors for Orchard Therapeutics’ gene therapies – indicated to treat primary immunodeficiencies – at its facility near Paris, France.
Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.
Daiichi Sankyo Company has signed an option agreement to develop Glycotope’s antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.
Chiome Bioscience has selected ProBioGen to develop and manufacture its monoclonal antibody LIV-1205, which is designed to combat liver cancer and solid tumours.
VirionHealth Ltd is poised to start Phase I trials of new biological antivirals - called defective interfering particles - after receiving £13m ($15m) from private equity group Abingworth.
OncoQR says its two-part therapeutic vaccines help the immune system to attack cancerous cells more effectively and with fewer side effects than conventional immunotherapies.
Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.
Regulators have granted CureVac a European patent for its mRNA vaccine and anti-PD-1 antibody technology designed to prevent and treat cancers and infectious diseases.
ImmunoCellular Therapeutics Ltd has halted a Phase III trial of its brain cancer cell therapy ICT-107 due to a lack of funds and is looking for a buyer or partner for the programme.
Germany’s Merck expands its partnership with F-star and EpimAb Biotherapeutics contracts WuXi Biologics. Welcome to our round-up of bispecific antibody news.
Merck & Co and Aduro Biotech have announced plans to test Keytruda combined with CRS-207 in patients suffering malignant pleural mesothelioma as a result of exposure to asbestos.
Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.
Contract manufacturer Goodwin Biotechnology will work with Minneapolis Medical Research Foundation (MMRF) to develop vaccines to treat opioid addiction.
